Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Vaginal
Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2016”
to their offering.

This report provides comprehensive information on the therapeutic
development for Vaginal Atrophy, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Vaginal
Atrophy and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Vaginal Atrophy Overview
  3. Therapeutics Development
  4. Pipeline Products for Vaginal Atrophy – Overview
  5. Pipeline Products for Vaginal Atrophy – Comparative Analysis
  6. Vaginal Atrophy – Therapeutics under Development by Companies
  7. Vaginal Atrophy – Therapeutics under Investigation by
  8. Vaginal Atrophy Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Vaginal Atrophy – Products under Development by Companies
  13. Vaginal Atrophy – Products under Investigation by
  14. Vaginal Atrophy – Companies Involved in Therapeutics Development
  • EndoCeutics, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Mithra Pharmaceuticals S.A.
  • PEPTONIC medical AB
  • TherapeuticsMD, Inc.

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
, Sexual
and Reproductive Health Drugs